-
Something wrong with this record ?
Monitoring of fibrinolytic system activity with plasminogen, D-dimers and FDP in primary total knee arthroplasty (TKA) after topical, intravenous or combined administration of tranexamic acid
J. Lostak, J. Gallo, L. Slavik, J. Zapletalova, L. Balaz
Language English Country Czech Republic
Document type Journal Article, Randomized Controlled Trial
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
31551606
DOI
10.5507/bp.2019.034
Knihovny.cz E-resources
- MeSH
- Antifibrinolytic Agents administration & dosage MeSH
- Administration, Topical MeSH
- Osteoarthritis, Knee surgery MeSH
- Fibrin Fibrinogen Degradation Products metabolism MeSH
- Hematocrit MeSH
- Hemoglobins metabolism MeSH
- Administration, Intravenous MeSH
- Blood Loss, Surgical * MeSH
- Tranexamic Acid administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Plasminogen metabolism MeSH
- Postoperative Hemorrhage epidemiology MeSH
- Aged MeSH
- Arthroplasty, Replacement, Knee methods MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
AIM: We assessed various ways of tranexamic acid (TXA) administration on the fibrinolytic system. Blood loss, transfusions, drainage and haematoma were secondary outcomes. METHODS: In this prospective study, we examined 100 patients undergoing primary total knee arthroplasty (TKA) between June and November 2018. Patients were randomly assigned to 4 groups according to the following TXA regimens: 1) loading dose 15 mg TXA/kg single intravenous administration applied at initiation of anesthesia (IV1); 2) loading dose 15 mg TXA/kg + additional dose 15 mg TXA/kg 6 h after the first application of TXA (IV2); 3) IV1 regime in combination with a local wash of 2 g of TXA in 50 mL of saline (COMB); 4) topical administration of 2 g of TXA in 50 mL of saline (TOP). RESULTS: Systemic fibrinolysis interference was insignificant in all of the regimens; we did not detect significant differences between IV1, IV2 and COMB in the monitored parameters within the elapsed time after the TKA; IV regimes had the lowest total drainage blood loss; the lowest blood loss was associated with the IV1 and IV2 regimens (IV1, IV2 < COMB < TOP); the lowest incidence of haematomas was in patients treated with TXA topically (i.e., in COMB + TOP). CONCLUSION: The largest antifibrinolytic effect was associated with intravenous administration of TXA. In terms of blood loss, intravenously administered TXA can interfere with the processes associated with the formation of the fibrin plug more efficiently than the simple washing of wound surfaces with TXA.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21014142
- 003
- CZ-PrNML
- 005
- 20210528092857.0
- 007
- ta
- 008
- 210504s2020 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2019.034 $2 doi
- 035 __
- $a (PubMed)31551606
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Lošťák, Jiří $7 xx0199227 $u Department of Orthopaedics, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 245 10
- $a Monitoring of fibrinolytic system activity with plasminogen, D-dimers and FDP in primary total knee arthroplasty (TKA) after topical, intravenous or combined administration of tranexamic acid / $c J. Lostak, J. Gallo, L. Slavik, J. Zapletalova, L. Balaz
- 504 __
- $a Literatura
- 520 9_
- $a AIM: We assessed various ways of tranexamic acid (TXA) administration on the fibrinolytic system. Blood loss, transfusions, drainage and haematoma were secondary outcomes. METHODS: In this prospective study, we examined 100 patients undergoing primary total knee arthroplasty (TKA) between June and November 2018. Patients were randomly assigned to 4 groups according to the following TXA regimens: 1) loading dose 15 mg TXA/kg single intravenous administration applied at initiation of anesthesia (IV1); 2) loading dose 15 mg TXA/kg + additional dose 15 mg TXA/kg 6 h after the first application of TXA (IV2); 3) IV1 regime in combination with a local wash of 2 g of TXA in 50 mL of saline (COMB); 4) topical administration of 2 g of TXA in 50 mL of saline (TOP). RESULTS: Systemic fibrinolysis interference was insignificant in all of the regimens; we did not detect significant differences between IV1, IV2 and COMB in the monitored parameters within the elapsed time after the TKA; IV regimes had the lowest total drainage blood loss; the lowest blood loss was associated with the IV1 and IV2 regimens (IV1, IV2 < COMB < TOP); the lowest incidence of haematomas was in patients treated with TXA topically (i.e., in COMB + TOP). CONCLUSION: The largest antifibrinolytic effect was associated with intravenous administration of TXA. In terms of blood loss, intravenously administered TXA can interfere with the processes associated with the formation of the fibrin plug more efficiently than the simple washing of wound surfaces with TXA.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a aplikace lokální $7 D000287
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antifibrinolytika $x aplikace a dávkování $7 D000933
- 650 _2
- $a totální endoprotéza kolene $x metody $7 D019645
- 650 12
- $a krvácení při operaci $7 D016063
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibrin-fibrinogen - produkty degradace $x metabolismus $7 D005338
- 650 _2
- $a hematokrit $7 D006400
- 650 _2
- $a hemoglobiny $x metabolismus $7 D006454
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a artróza kolenních kloubů $x chirurgie $7 D020370
- 650 _2
- $a plazminogen $x metabolismus $7 D010958
- 650 _2
- $a pooperační krvácení $x epidemiologie $7 D019106
- 650 _2
- $a kyselina tranexamová $x aplikace a dávkování $7 D014148
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Gallo, Jiří $7 xx0019005 $u Department of Orthopaedics, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Slavík, Luděk $7 xx0081908 $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Zapletalová, Jana $7 xx0111614 $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Baláž, Ľuboš $7 xx0257009 $u Department of Orthopaedics, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 164, č. 2 (2020), s. 168-176
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31551606 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20210504 $b ABA008
- 991 __
- $a 20210524133516 $b ABA008
- 999 __
- $a ok $b bmc $g 1657555 $s 1134530
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 164 $c 2 $d 168-176 $e 20190916 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20210504